Analyst sees positive future for Merck KGaA in MS market, as FDA accepts Mavenclad for review

Analyst sees positive future for Merck KGaA in MS market, as FDA accepts Mavenclad for review

Source: 
The Pharma Letter
snippet: 

The US Food and Drug Administration’s acceptance of Merck KGaA’s (MRK: DE) resubmitted application for Mavenclad (cladribine), seven years after the original application,  is seen as a positive in terms of the German drugmakers future in the multiple sclerosis therapy sector.